GSK shares analysts get out the red pens after FDA knock-back wipes £3bn from drug maker's value

• click to rate

  Posted by Two Blokes Jul 18 - Filed in Stock - 2 views
  
  Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell 6% on Thursday, wiping more than £3bn from its market value, after a US advisory committee delivered a serious blow to the drugmaker's oncology ambitions. The Food and Drug Administration's (FDA) Oncology Drugs Advisory Committee (ODAC) voted against approving GSK's multiple myeloma drug Blenrep in two separate phase III trials.